CONGRESS PRESENTATIONS
-
ViiV-Sponsored Data
Cabotegravir Prevention
Baker DM, et al.
Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study×Baker DM, et al.
Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study- Full Poster
- Title
- Key Takeaways
- Introduction
- Methods
- Results
- Figure 1. HCP Perceptions of CAB LA of Appropriateness and Feasibility
- Figure 2. HCP Perceptions of CAB LA
- Figure 3. Factors Related to Patient Identification, Counseling, and Adherence
- Figure 4. HCP Strategies for Supporting CAB LA Patient Adherence
- Figure 5. Usefulness of Provider Support Tools
- Conclusions
- Disclaimer
Hsu RK, et al.
PrEP Decision Factors: a CHORUS Healthcare Professional Survey×- Full Poster
- Title
- Background
- Methods
- Results
- Figure 1. Self-reported PrEP knowledge, effectiveness, and importance
- Figure 2. Conversations about PrEP
- Figure 3. Among prescribers, likelihood of prescribing PrEP and LA PrEP
- Figure 4. Importance of various patient factors for recommending PrEP
- Figure 5. Among prescribers, likelihood of prescribing LA PrEP to various individuals, by patient and sexual partner(s)
- Figure 6. Among prescribers, likelihood of prescribing LA PrEP to various individuals, by patient and characteristic
- Discussion
- Key Findings
- Acknowledgments
- Disclaimer
Mills A, et al.
Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort×Mills A, et al.
Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort- Title
- Disclosures
- Background & Objectives
- Pre-exposure prophylaxis (PrEP) landscape
- Cabotegravir long-acting (CAB LA) PrEP dosing schedule
- Objectives and Methods
- Study objectives
- OPERA The Longitudinal Cohort
- Study population
- Results
- Baseline characteristics of CAB LA PrEP and oral PrEP users (1)
- Baseline characteristics of CAB LA PrEP and oral PrEP users (2)
- Complete vs. incomplete initiation among all CAB LA PrEP users
- Complete vs. incomplete initiation among all CAB LA PrEP users (continued)
- On-time injections among complete initiators
- On-time injections among complete initiators (continued)
- Delayed injections among complete initiators
- Delayed injections among complete initiators (continued)
- Missed continuation injections among complete initiators
- Missed continuation injections among complete initiators (continued)
- HIV testing within 1 week before/at 1st CAB LA PrEP injection
- HIV testing within 1 week before/at subsequent CAB LA PrEP injection
- HIV acquisition among CAB LA PrEP users
- Case #1
- Case #2
- Discussion
- Key findings (1)
- Key findings (2)
- Strengths & limitations
- Acknowledgements
- Disclaimer
Ramgopal M, et al.
Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort×Ramgopal M, et al.
Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort- Title
- Disclosures
- Background
- Study Objectives
- Methods
- Study Design
- Study Outcomes
- Results - 2 Year Analysis
- Study Population
- Characteristics at Regimen Initiation
- HIV Risk Factors and Prior PrEP Use at Initiation
- Persistence
- Discontinuations
- On Time Injections
- HIV Screening and Seroconversion
- Safety
- Limitations
- Conclusions
- Thank You
- Disclaimer
Cabotegravir Treatment
Altamirano JA, et al.
Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort×- Full Poster
- Title
- Background
- Methods
- Results
- Table 2. Clinical characteristics at initiation of CAB+RPV LA injections, stratified by baseline VL
- Table 3. ART history at initiation of CAB+RPV LA injections, stratified by baseline VL
- Figure 1. CAB+RPV LA dosing at initiation and at study end among complete initiators, stratified by baseline VL
- Discussion
- Key Findings
- Acknowledgements
- Disclaimer
Lackey PC, et al.
Improved Testing for Chronic Disease Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA Cohort×Lackey PC, et al.
Improved Testing for Chronic Disease Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA Cohort- Full Poster
- Title
- Background
- Methods
- Results
- Table 2. Calculations of risk score composites over follow-up, by ART group
- Figure 1. Proportions of PWH who received lipid testing over follow-up, by ART group
- Figure 2. Proportions of PWH who received serum glucose testing over follow-up, by ART group
- Discussion
- Key Findings
- Reference, Acknowledgements
- Disclaimer
Dolutegravir-based Regimens
Fostemsavir
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect With Our Medical Experts
Find My ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1‑888‑226‑8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch